Community-based rehabilitation intervention for people with schizophrenia in Ethiopia (RISE): results of a 12-month cluster-randomised controlled trial

Background: Community-based rehabilitation (CBR) is recommended to address the social and clinical needs of people with schizophrenia in resource-poor settings. We evaluated the effectiveness of CBR at reducing disability at 12 months in people with schizophrenia who had disabling illness after havi...

Full description

Bibliographic Details
Main Authors: Asher, L. (Author), Birhane, R. (Author), De Silva, M. (Author), Fekadu, A. (Author), Hanlon, C. (Author), Medhin, G. (Author), Patel, V. (Author), Selamu, M. (Author), Weiss, H.A (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 06290nam a2200889Ia 4500
001 10-1016-S2214-109X-22-00027-4
008 220420s2022 CNT 000 0 und d
020 |a 2214109X (ISSN) 
245 1 0 |a Community-based rehabilitation intervention for people with schizophrenia in Ethiopia (RISE): results of a 12-month cluster-randomised controlled trial 
260 0 |b Elsevier Ltd  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1016/S2214-109X(22)00027-4 
520 3 |a Background: Community-based rehabilitation (CBR) is recommended to address the social and clinical needs of people with schizophrenia in resource-poor settings. We evaluated the effectiveness of CBR at reducing disability at 12 months in people with schizophrenia who had disabling illness after having had the opportunity to access facility-based care for 6 months Methods: This cluster-randomised controlled trial was conducted in a rural district of Ethiopia. Eligible clusters were subdistricts in Sodo district that had not participated in the pilot study. Available subdistricts were randomised (in a 1:1 ratio) to either the intervention group (CBR plus facility-based care) or to the control group (facility-based care alone). An optimisation procedure (accounting for the subdistrict mean WHO Disability Assessment Schedule (WHODAS) score and the potential number of participants per subdistrict) was applied for each of the eight health facilities in the district. An independent statistician, masked to the intervention or control label, used a computer programme to randomly choose the allocation sequence from the set of optimal ones. We recruited adults with disabling illness as a result of schizophrenia. The subdistricts were eligible for inclusion if they included participants that met the eligibility criteria. Researchers recruiting and assessing participants were masked to allocation status. Facility-based care was a task-shared model of mental health care integrated within primary care. CBR was delivered by lay workers over a 12-month period, comprising of home visits (psychoeducation, adherence support, family intervention, and crisis management) and community mobilisation. The primary outcome was disability, measured with the proxy-rated 36-item WHODAS score at 12 months. The subdistricts that had primary outcome data available were included in the primary analysis. This study is registered with ClinicalTrials.gov, NCT02160249. Findings: Enrolment took place between Sept 16, 2015 and Mar 11, 2016. 54 subdistricts were randomised (27 to the CBR plus facility-based care group and 27 to the facility-based care group). After exclusion of subdistricts without eligible participants, we enrolled 79 participants (66% men and 34% women) from 24 subdistricts assigned to CBR plus facility-based care and 87 participants (59% men and 41% women) from 24 subdistricts assigned to facility-based care only. The primary analysis included 149 (90%) participants in 46 subdistricts (73 participants in 22 subdistricts in the CBR plus facility-based care group and 76 participants in 24 subdistricts in the facility-based care group). At 12 months, the mean WHODAS scores were 46·1 (SD 23·3) in the facility-based care group and 40·6 (22·5) in the CBR plus facility-based care group, indicating a favourable intervention effect (adjusted mean difference −8·13 [95% CI −15·85 to −0·40]; p=0·039; effect size 0·35). Four (5%) CBR plus facility-based care group participants and nine (10%) facility-based care group participants had one or more serious adverse events (death, suicide attempt, and hospitalisation). Interpretation: CBR delivered by lay workers combined with task-shared facility-based care, was effective in reducing disability among people with schizophrenia. The RISE study CBR model is particularly relevant to low-income countries with few mental health specialists. Funding: Wellcome Trust. © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 
650 0 4 |a adherence support 
650 0 4 |a adult 
650 0 4 |a antidepressant agent 
650 0 4 |a Article 
650 0 4 |a Barthel index 
650 0 4 |a Brief Psychiatric Rating Scale 
650 0 4 |a Butajira Functioning Scale 
650 0 4 |a caregiver 
650 0 4 |a chlorpromazine 
650 0 4 |a Client Service Receipt Inventory 
650 0 4 |a Clinical Global Impression scale 
650 0 4 |a clinical outcome 
650 0 4 |a cognition 
650 0 4 |a community based rehabilitation 
650 0 4 |a comparative effectiveness 
650 0 4 |a controlled study 
650 0 4 |a crisis management 
650 0 4 |a daily life activity 
650 0 4 |a disease severity 
650 0 4 |a effect size 
650 0 4 |a Ethiopia 
650 0 4 |a family therapy 
650 0 4 |a female 
650 0 4 |a follow up 
650 0 4 |a haloperidol 
650 0 4 |a health care facility 
650 0 4 |a home visit 
650 0 4 |a hospital readmission 
650 0 4 |a hospitalization 
650 0 4 |a human 
650 0 4 |a information processing 
650 0 4 |a major clinical study 
650 0 4 |a male 
650 0 4 |a masking 
650 0 4 |a medical procedures 
650 0 4 |a mental health 
650 0 4 |a mental health care 
650 0 4 |a mental health service 
650 0 4 |a Morisky Medication Adherence Scale 
650 0 4 |a nurse 
650 0 4 |a outcome assessment 
650 0 4 |a physical activity 
650 0 4 |a primary medical care 
650 0 4 |a psychoeducation 
650 0 4 |a psychosocial care 
650 0 4 |a psychosocial rehabilitation 
650 0 4 |a randomized controlled trial 
650 0 4 |a schizophrenia 
650 0 4 |a social status 
650 0 4 |a social support 
650 0 4 |a suicide attempt 
650 0 4 |a trust 
650 0 4 |a voluntary worker 
650 0 4 |a World Health Organization Disability Assessment Schedule 
650 0 4 |a World Health Organization Disability Assessment Schedule 2.0 
700 1 0 |a Asher, L.  |e author 
700 1 0 |a Birhane, R.  |e author 
700 1 0 |a De Silva, M.  |e author 
700 1 0 |a Fekadu, A.  |e author 
700 1 0 |a Hanlon, C.  |e author 
700 1 0 |a Medhin, G.  |e author 
700 1 0 |a Patel, V.  |e author 
700 1 0 |a Selamu, M.  |e author 
700 1 0 |a Weiss, H.A.  |e author 
773 |t The Lancet Global Health